Role of Cyclic Nucleotide Metabolism in the Pathophysiology of Atopic Eczema

  • J. M. Hanifin
  • S. Ch. Chan


A study of the non-allergic, pharmacological mechanisms establishes a separate basic plane of investigation in atopic eczema (AE). Considerable clinical research is focussed at the level of environmental exacerbants while the more fundamental level — the realm of the genetically determined, constitutional predisposition to atopy — is largely ignored. Szentivanyi quoted Rackemann, who recognised this disparity in 1931: “The situation is somewhat analogous to that of a loaded gun. A good deal of knowledge is being obtained about a great variety of triggers (extrinsic and intrinsic causes) which fire the charge; but why is the gun loaded? And, what constitutes the load?” [1, 2]


Atopic Eczema Adenylate Cyclase Histamine Release Allergy Clin Immunol Cyclic Nucleotide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Szentivanyi A (1968) The beta adrenergic theory of the atopic abnormality in bronchial asthma. J Allergy 42: 203–232CrossRefGoogle Scholar
  2. 2.
    Rackemann FM (1931) Clinical allergy, particularly asthma and hayfever. Mechanism and treatment. Macmillan, New York, p 3Google Scholar
  3. 3.
    Geha RS (1986) Introduction to monograph on atopic dermatitis. Clin Rev Allergy 4: 1–2Google Scholar
  4. 4.
    Saarinen UM (1984) Transfer of latent atopy by bone marrow transplantation? A case report. J Allergy Clin Immunol 74: 196–200PubMedCrossRefGoogle Scholar
  5. 5.
    Saurat JH (1985) Eczema in primary immune deficiencies. Clues to the pathogenesis of atopic dermatitis with special reference to the Wiskott-Aldrich syndrome. Acta Derm Venereol [Suppl] (Stockh.) 114: 125–128Google Scholar
  6. 6.
    Galey CI, Edelstein RA, Chan SC, Hanifin JM (1986) Altered leukocyte phosphoinositide metabolism in atopic dermatitis. J Invest Dermatol 86: 476Google Scholar
  7. 7.
    Fishel CW, Szentivanyi A, Talmadge DW (1964) Adrenergic factors in Bordetella pertussis-induced histamine and serotonin hypersensitivity of mice. In: Landy M, Braun W (eds) Bacterial endotoxins. Rutgers University Press, New Brunswick, pp 474–481Google Scholar
  8. 8.
    Kurose H, Katada T, Amano T, Ui M (1983) Specific uncoupling by islet-activating protein, pertussis toxin, of negative signal transduction via alpha-adrenergic, cholinergic, and opiate receptors in neuroblastoma glioma hybrid cells. J Biol Chem 258: 4870–4875PubMedGoogle Scholar
  9. 9.
    Hanifin JM (1986) Pharmacophysiology of atopic dermatitis. Clin Rev Allergy 4: 43–65PubMedGoogle Scholar
  10. 10.
    Snyderman SE (1965) An eczematoid dermatitis in histidine deficiency. J Pediatr 66: 212–215PubMedCrossRefGoogle Scholar
  11. 11.
    Rostenberg A Jr, Solomon LM (1968) Infantile eczema in systemic disease. Arch Dermatol 98: 41PubMedCrossRefGoogle Scholar
  12. 12.
    Rost G, Marchionini A (1932) Asthma-ekzem, Asthma-prurigo and Neurodermitis als allergische Hautkrankheiten. Würzb Abhandl Gesamtgeb Med 27: 337–344Google Scholar
  13. 13.
    MacKenna R, Lehmann H (1963) Further observations on the glucose-tolerance test in skin disease. Lancet 1: 1393–1395CrossRefGoogle Scholar
  14. 14.
    Hamza SH, El-Mazny HR, Abdallah MA (1978) Glucose tolerance in eczema. Br J Dermatol 98: 289–292CrossRefGoogle Scholar
  15. 15.
    Lockey S, Glennon J, Reed C (1967) Comparison of some metabolic responses in normal and asthmatic subjects to epinephrine and glucagon. J Allergy 40: 349–354PubMedCrossRefGoogle Scholar
  16. 16.
    Grieco M, Pierson R, Sunyer F (1968) Comparison of the circulatory and metabolic effects of isoproterenol, epinephrine and methoxamine in normal and asthmatic subjects. Am J Med 44: 863–872PubMedCrossRefGoogle Scholar
  17. 17.
    Stokes JH (1930) The eczema problem. Am J Med Sci 179: 69–82CrossRefGoogle Scholar
  18. 18.
    Readett MD (1955) Constitutional eczema and thyroid disease. J Invest Dermatol 24: 126–139Google Scholar
  19. 19.
    Carlson JA (1965) Hypothyroidism in atopics. Ann Allergy 23: 331–334Google Scholar
  20. 20.
    Weber R, Roth G, Kierland R (1955) Further contributions to the vascular physiology of atopic dermatitis. J Invest Dermatol 24: 19–30PubMedGoogle Scholar
  21. 21.
    Schwartz HJ (1966) The relationship of thyroid disease and the atopic state. Ann Allergy 24: 234–237PubMedGoogle Scholar
  22. 22.
    Musaph H (1964) Itching and scratching. Davis, Philadelphia Ann Allergy 24: 234–237Google Scholar
  23. 23.
    Allerhand M, Gough H, Grais M (1950) Personality factors in neurodermatitis: a preliminary study. Psychosom Med 12: 386–390PubMedGoogle Scholar
  24. 24.
    Alexander F (1950) Emotional factors in skin diseases. Norton, New York, pp 164–169Google Scholar
  25. 25.
    Williams D (1951) Management of atopic dermatitis in children: control of the maternal rejection factor. Arch Dermatol and Syphilol 63: 545–560CrossRefGoogle Scholar
  26. 26.
    Sulzberger MB (1955) Atopic dermatitis: its clinical and historic picture. In: Baer RL (ed) Atopic dermatitis. New York University Press, New York, pp 11–42Google Scholar
  27. 27.
    Rostenberg A (1959) Psychosomatic concepts in atopic dermatitis–a critique. Arch Dermatol 79: 692–699CrossRefGoogle Scholar
  28. 28.
    Kalz F, Wittkower ED, Vavrusk GW, Telner P, Ferguson S (1957) Studies on vascular skin responses in atopic dermatitis: the influence of psychological factors. J Invest Dermatol 29: 67–80PubMedGoogle Scholar
  29. 29.
    Jordan JM, Whitlock FA (1972) Emotions and the skin: the conditioning of scratch responses in cases of atopic dermatitis. Br J Dermatol 86: 574–585PubMedCrossRefGoogle Scholar
  30. 30.
    Graham DT, Wolf S (1953) The relation of Eczema to attitude and to vascular reactions of the human skin. J Lab Clin Med 42: 238–254PubMedGoogle Scholar
  31. 31.
    Jacquet L (1904) In: Besnier E, Brocq L, Jacquet L, (eds) La pratique dermatologique, vol 5. Masson, ParisGoogle Scholar
  32. 32.
    Foreman JC, Piotrowski W (1984) Peptides and histamine release. J Allergy Clin Immunol 74: 127–131PubMedCrossRefGoogle Scholar
  33. 33.
    Ebertz JM, Hirshman CA, Kettelkamp BS, Uno H, Hanifin JM (1987) Substance P-induced histamine release in human cutaneous mast cells. J Invest Dermatol 88: 682685Google Scholar
  34. 34.
    Sulzberger MB, Herrmann F, Borota A, Strauss MB (1953) Studies of sweating. VI. On the urticariogenic properties of human sweat. J Invest Dermatol 21: 293–303Google Scholar
  35. 35.
    Sulzberger MB, Herrmann F, Zak FG (1947) Studies of sweating. I. Preliminary report with particular emphasis on a sweat retention syndrome. J Invest Dermatol 9: 221–242Google Scholar
  36. 36.
    Davis MJ, Lawler JC (1958) Observations on the delayed blanch phenomenon in atopic subjects. J Invest Dermatol 30: 127–132PubMedGoogle Scholar
  37. 37.
    Prose PH (1965) Pathologic changes in eczema. J Pediatr 66: 178–199PubMedCrossRefGoogle Scholar
  38. 38.
    Rovensky J, Saxl 0 (1964) Differences in the dynamics of sweat secretion in atopic children. J Invest Dermatol 43: 171–176Google Scholar
  39. 39.
    Warndorff JA (1970) The response of the sweat gland to acetylcholine in atopic subjects. Br J Dermatol 83: 306–311PubMedCrossRefGoogle Scholar
  40. 40.
    Kaliner M (1976) The cholinergic nervous system and immediate hypersensitivity. I. Eccrine sweat responses in allergic patients. J Allergy Clin Immunol 58: 308–315PubMedCrossRefGoogle Scholar
  41. 41.
    Hemels HGWM (1970) The effect of propranolol on the acetylcholine induced sweat gland response in atopic and non-atopic subjects. Br J Dermatol 83: 312–314PubMedCrossRefGoogle Scholar
  42. 42.
    Foster JG, Haspineall FR, Mollel CL (1971) Effects of propranolol on the response of human eccrine sweat glands to acetylcholine. Br J Dermatol 85: 363–367PubMedCrossRefGoogle Scholar
  43. 43.
    Kiistala R (1982) Stimulated local sweating response in atopic dermatitis. Abstracts, XVI Congressus Internationalis Dermatologiae, Tokyo, p 320Google Scholar
  44. 44.
    Murphy GM, Smith SE, Greaves MW (1984) Autonomic function in cholinergic urticaria and atopic eczema. Br J Dermatol 110: 581–586PubMedCrossRefGoogle Scholar
  45. 45.
    Grosshans E, Woehl M (1982) Troubles vasomoteurs, sudoraux et sebaces de l’eczema constitutionnel. Ann Dermatol Venereol 109: 151–162PubMedGoogle Scholar
  46. 46.
    Sato K, Sato F (1983) Individual variations in structure and function of human eccrine sweat gland. Am J Physiol 245: 203–208Google Scholar
  47. 47.
    Whitfield A (1938) On the white reaction (white line) in dermatology. Br J Dermatol 50: 71–82CrossRefGoogle Scholar
  48. 48.
    Uehara M, Ofuji S (1977) Abnormal vascular reactions in atopic dermatitis. Arch Dermatol 113: 627–629PubMedCrossRefGoogle Scholar
  49. 49.
    Champion RH (1961) Abnormal vascular reactions in atopic eczema. Br J Dermatol 81: 12–15Google Scholar
  50. 50.
    Eyster WH, Roth GM, Kierland RR (1952) Studies on the peripheral vascular physiology of patients with atopic dermatitis. J Invest Dermatol 18: 37–46PubMedCrossRefGoogle Scholar
  51. 51.
    Lobitz WC Jr, Campbell CF (1953) Physiologic studies in atopic dermatitis (disseminated neurodermatitis). Arch Dermatol Syphilol 67: 575–589CrossRefGoogle Scholar
  52. 52.
    Ramsay C (1969) Vascular changes accompanying white dermographism and delayed blanch in atopic dermatitis. Br J Dermatol 81: 37–42PubMedCrossRefGoogle Scholar
  53. 53.
    Thune P, Rajka G (1980) Small vessel reactivity in atopic dermatitis. Acta Derm Venereol [Suppl] (Stockh.) 92: 30–32Google Scholar
  54. 54.
    Juhlin L (1961) Skin reactions to iontophoretically, administered epinephrine and norepinephrine in atopic dermatitis. J Invest Dermatol 37: 201–205PubMedGoogle Scholar
  55. 55.
    Juhlin L (1962) Vascular skin reactions in atopic dermatitis. Acta Derm Venereol (Stockh.) 42: 218–229Google Scholar
  56. 56.
    Verma BS, Gulati OD, Gokhale SD, Shah KC (1964) Guanethidine and phenoxybenzamine in atopic dermatitis. Arch Dermatol 90: 414–417PubMedCrossRefGoogle Scholar
  57. 57.
    Thomsen K, Osmundsen PE (1965) Guanethidine in the treatment of atopic dermatitis. Arch Dermatol 92: 418–421PubMedCrossRefGoogle Scholar
  58. 58.
    Lobitz WC Jr, Heller M, Dobsen RL (1957) Physiologic studies in atopic dermatitis (disseminated neurodermatitis): the effect of denervation on the “delayed blanch phenomenon.” Arch Dermatol 75: 228–229Google Scholar
  59. 59.
    Reed WB, Kierland RR (1958) Vascular reactions in chronically inflamed skin. Arch Dermatol 77: 181–186CrossRefGoogle Scholar
  60. 60.
    Barker AF, Hanifin JM, Hirshman CA, D’Silva R (1985) Airway hyperreaktivity in patients with atopic dermatitis ( AD ). Am Rev Respir Dis 131: A41Google Scholar
  61. 61.
    Smith LJ, Shelhamer JH, Kaliner M (1980) Cholinergic nervous sysem and immediate hypersensitivity. II. An analysis of pupillary responses. J Allergy Clin Immunol 66: 374–378Google Scholar
  62. 62.
    Clark LL, Kierland RR, Roth GM (1960) Methacholine chloride. Arch Dermatol 82: 957–964PubMedCrossRefGoogle Scholar
  63. 63.
    Scott A (1962) Acetylcholine in normal and diseased skin. Br J Dermatol 74: 317–322PubMedCrossRefGoogle Scholar
  64. 64.
    Rajka G (1975) Atopic dermatitis. Saunders, London Role of Cyclic Nucleotide Metabolism 243Google Scholar
  65. 65.
    Henderson WR, Shelhamer JH, Rheingold DB, Smith LJ, Evans R, Kaliner M (1979) Alpha-adrenergic hyper-responsiveness in asthma. N Engl J Med 300: 642–647PubMedCrossRefGoogle Scholar
  66. 66.
    Barnes P, Fitzgerald G, Brown M, Dollery C (1980) Nocturnal asthma and changes in circulating epinephrine, histamine and cortisol. N Engl J Med 303: 263–267PubMedCrossRefGoogle Scholar
  67. 67.
    Soughton RB, DeOreo G, Clendenning W (1960) Effects of intradermal injection of vasopressors in normal and diseased human skin. Arch Dermatol 82: 150–157Google Scholar
  68. 68.
    Solomon LM, Wentzel HE, Tulsky E (1964) The physiological disposition of C14-norepinephrine in patients with atopic dermatitis and other dermatoses. J Invest Dermatol 43: 193–200PubMedGoogle Scholar
  69. 69.
    Moller H, Rorsman G (1958) Studies on vascular permeability factors with sodium fluorescein, II. The effect of intracutaneously injected histamine and serum in patients with atopic dermatitis. Act Derm Venereol (Stockh.) 38: 243–250Google Scholar
  70. 70.
    Coulson IH, Holden CA (1988) Cutaneous reactions to intradermal substance P and histamine in atopic dermatitis. J Invest Dermatol 91: 396Google Scholar
  71. 71.
    Williams DH (1938) Skin temperature reaction to histamine in atopic dermatitis (disseminated neurodermatitis). J Invest Dermatol 1: 119–129CrossRefGoogle Scholar
  72. 72.
    Sampson HA, Jolie PL (1984) Increased plasma histamine concentrations after food challenges in children with atopic dermatitis. N Engl J Med 311: 372–376PubMedCrossRefGoogle Scholar
  73. 73.
    Eppinger H (1913) Quoted by Best CH, McHenry EW (1931) Histamine. Physiol Rev 11: 371–477Google Scholar
  74. 74.
    Harmer IM, Harris KE (1926) Observations on the vascular reactions in a man in response to histamine. Heart 13: 381–394Google Scholar
  75. 75.
    Mihm MC Jr, Soter NA, Dvorak HF, Austen KF (1976) The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol 67: 305–312PubMedCrossRefGoogle Scholar
  76. 76.
    Johnson HH, DeOreo GA, Lascheid WP, Mitchell F (1960) Skin histamine levels in chronic atopic dermatitis. J Invest Dermatol 34: 237–238PubMedGoogle Scholar
  77. 77.
    Hanifin JM (1977) Type I hypersensitivity diseases of the skin: divergent aspects of urticaria and atopic dermatitis. Ann Allergy 39: 153–160PubMedGoogle Scholar
  78. 78.
    Ring J, Senter T, Cornell RC, Arroyave CM, Tan EM (1979) Plasma complement and histamine changes in atopic dermatitis. Br J Dermatol 100: 512–530CrossRefGoogle Scholar
  79. 79.
    Lichtenstein LM, Margolis S (1968) Histamine release in vitro: inhibition by catecholamines and methylxanthines. Science 161: 902–904PubMedCrossRefGoogle Scholar
  80. 80.
    Orange RP, Austen WG, Austen KF (1971) Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. I. Modulation by agents influencing cellular levels of cyclic 3’5’-adenosine monophosphate. J Exp Med [Suppl] 134: 136–148Google Scholar
  81. 81.
    Lebel B, Venencie PY, Saurat JH et al. (1980) Anti-IgE induced histamine release from basophils in children with atopic dermatitis. Acta Derm Venereol [Suppl] (Stockh.) 92: 57Google Scholar
  82. 82.
    Butler JM, Chan SC, Stevens S, Hanifin JM (1983) Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis. J Allergy Clin Immunol 71: 440CrossRefGoogle Scholar
  83. 83.
    Bernstein RA, Linarelli L, Facktor MA et al. (1972) Decreased urinary adenosine 3’5’ monophosphate (cyclic AMP) in asthmatics. J Lab Clin Med 80: 772–779PubMedGoogle Scholar
  84. 84.
    Parker CW, Smith JW (1973) Alterations in cyclic adenosine monophosphate metabolism in human bronchial asthma. I. Leukocyte responsiveness to betaadrenergic agents. J Clin Invest 52: 48–59Google Scholar
  85. 85.
    Logsdon PJ, Middleton E Jr, Coffey RG (1972) Stimulation of leukocyte adenyl cyclase by hydrocortisone and isoproterenol in asthmatic and nonasthmatic subjects. J Allergy Clin Immunol 50: 45–56PubMedCrossRefGoogle Scholar
  86. 86.
    Can RH, Busse WW, Reed CE (1973) Failure of catecholamines to inhibit epidermal mitosis in vitro. J Allergy Clin Immunol 55: 255–262Google Scholar
  87. 87.
    Reed CE, Busse WW, Lee TP (1976) Adrenergic mechanisms and the adenyl cyclase system in atopic dermatitis. J Invest Dermatol 67: 333–338PubMedCrossRefGoogle Scholar
  88. 88.
    Reed CE (1974) Abnormal autonomic mechanisms in asthma. J Allergy Clin Immunol 53: 34–41PubMedCrossRefGoogle Scholar
  89. 89.
    Parker CW, Kennedy S, Eisen AZ (1977) Leukocyte and lymphocyte cyclic AMP responses in atopic eczema. J Invest Dermatol 68: 302–306PubMedCrossRefGoogle Scholar
  90. 90.
    Busse WW, Lantis SDH (1979) Impaired H2 histamine granulocyte release in active atopic eczema. J Invest Dermatol 73: 184–187PubMedCrossRefGoogle Scholar
  91. 91.
    Sano Y, Watt G, Townley RG (1983) Decreased mononuclear cell beta-adrenergic receptors in bronchial asthma: parallel studies of lymphocyte and granulocyte desensitization. J Allergy Clin Immunol 72: 495–503PubMedCrossRefGoogle Scholar
  92. 92.
    Pochet R, Delespesse G, DeMaubeuge J (1980) Characterization of beta-adrenoreceptors on intact circulating lymphocytes from patients with atopic dermatitis. Acta Derm Venereol [Suppl] (Stockh.) 92: 26–29Google Scholar
  93. 93.
    Galant SP, Underwood S, Allred S, Hanifin JM (1979) Beta adrenergic receptor binding on polymorphonuclear leukocytes in atopic dermatitis. J Invest Dermatol 72: 330–332PubMedCrossRefGoogle Scholar
  94. 94.
    Greenacre JK, Schofield P, Connolly ME (1978) Desensitization of the B-adrenoceptor of lymphocytes from normal subjects and asthmatic patients in vitro. Br J Clin Pharmacol 5: 199–210PubMedCrossRefGoogle Scholar
  95. 95.
    Morris HG (1980) Drug-induced desensitization of beta adrenergic receptors. J Allergy Clin Immunol 65: 83–86PubMedCrossRefGoogle Scholar
  96. 96.
    Safko MJ, Chan SC, Cooper KD, Hanifin JM (1981) Heterologous desensitization of leukocytes: a possible mechanism of beta adrenergic blockade in atopic dermatitis. J Allergy Clin Immunol 68: 218–225PubMedCrossRefGoogle Scholar
  97. 97.
    Chan SC, Grewe SR, Hanifin JM (1982) Functional desensitization associated with elevated cAMP phosphodiesterase in human mononuclear leukocytes. J Cyclic Nucleotide Res 8: 211–224PubMedGoogle Scholar
  98. 98.
    Grewe SR, Chan SC, Hanifin JM (1982) Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cAMP-agonist hyporesponsiveness. J Allergy Clin Immunol 70: 452–457PubMedCrossRefGoogle Scholar
  99. 99.
    Thompson WJ, Ross CP, Pledger WJ, Strada SJ (1976) Cyclic adenosine 3’:5’-monophosphate phosphodiesterase: distinct forms in human lymphocytes and monocytes. J Biol Chem 251: 4922PubMedGoogle Scholar
  100. 100.
    Holla SWJ, Hollman EP, Mier PD et al. (1972) Adenosine 3’5’-cyclic monophosphate phosphodiesterase in skin. II. Levels in atopic dermatitis. Br J Dermatol 86: 147–149Google Scholar
  101. 101.
    Grotti A, Guidotti A, Mannaioni PF, Zilletti L (1966) The influence of adrenotropic drugs and noradrenaline on the histamine release in cardiac anaphylaxis in vitro. J Physiol 184: 924Google Scholar
  102. 102.
    Kaliner MA, Orange RP, Austen KF (1972) Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. IV. Enhancement by cholinergic and alpha adrenergic stimulation. J Exp Med 136: 556–567Google Scholar
  103. 103.
    Cooper KD, Kang K, Chan SC, Hanifin JM (1985) Phosphodiesterase inhibition by Ro20–1724 reduces hyper-IgE synthesis by atopic dermatitis cell in vitro. J Invest Dermatol 84: 477–482PubMedCrossRefGoogle Scholar
  104. 104.
    Heskel NS, Chan SC, Thiel ML, Stevens SR, Casperson LS, Hanifin JM (1984) Elevated umbilical cord blood leukocyte cyclic adenosine monophosphate-phosphodiesterase activity in children with atopic parents. J Am Acad Dermatol 11: 422–426PubMedCrossRefGoogle Scholar
  105. 105.
    Cassel D, Selinger Z (1977) Mechanism of adenylate cyclase activation by cholera toxin. Inhibition of GTP hydrolysis at the regulatory site. Proc Natl Acad Sci USA 74 (8): 3307–3311PubMedCrossRefGoogle Scholar
  106. 106.
    Epstein E (1946) Theophylline ethylenediamine as an antipruritic agent. Arch Dermatol Syphilol 53: 281–284CrossRefGoogle Scholar
  107. 107.
    Guistina TA, Chan SC, Thiel MD et al. (1984) Increased leukocyte sensitivity to phosphodiesterase inhibitors in atopic dermatitis: tachyphylaxis after theophylline therapy. J Allergy Clin Immunol 74: 252–257CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • J. M. Hanifin
  • S. Ch. Chan

There are no affiliations available

Personalised recommendations